The estimated Net Worth of William M. Mc Clements is at least $213 mil dollars as of 29 February 2016. William Clements owns over 2,000 units of Merrimack Pharmaceuticals Inc stock worth over $212,909 and over the last 12 years William sold MACK stock worth over $0.
William has made over 5 trades of the Merrimack Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently William bought 2,000 units of MACK stock worth $11,440 on 29 February 2016.
The largest trade William's ever made was buying 7,000 units of Merrimack Pharmaceuticals Inc stock on 27 November 2013 worth over $25,270. On average, William trades about 1,545 units every 75 days since 2012. As of 29 February 2016 William still owns at least 14,072 units of Merrimack Pharmaceuticals Inc stock.
You can see the complete history of William Clements stock trades at the bottom of the page.
William's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA, 02139.
Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy y Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include: